BACKGROUND: Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies. However, the impact of ALC relative to that of other prognostic factors on the outcome of children with acute lymphoblastic leukemia (ALL) treated in recent trials is unknown. METHODS: Outcomes of 399 patients aged ≤18 years with newly diagnosed ALL who were enrolled in the Total Therapy XV study at St. Jude Children's Research Hospital were analyzed according to ALC at the end of remission induction therapy. RESULTS: An ALC ≥500 cells/μL was significantly more prevalent among patients with B-lineage ALL, in those with favorable presenting features, and in those who achieved negative minimal residual disease (MRD) status on day 43 of treatment. Both overall survival (OS) and event-free survival (EFS) were superior among patients with higher ALC, but only the association with OS was statistically significant in a univariate analysis. In multivariable analyses, ALC was not a significant predictor of outcome after controlling for age, leukocyte count, lineage, risk group, and MRD status at the end of induction (P > .1 for all comparisons). However, among MRD-negative patients, those with low ALC had a 5-year OS rate of 84.2% ± 8.9% versus 97.3% ± 1.0% for patients with higher ALC (P = .036). CONCLUSIONS: ALC at the end of induction is related to favorable presenting features and good initial treatment response but does not independently predict outcome in the context of contemporary, MRD-guided therapy.
BACKGROUND: Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies. However, the impact of ALC relative to that of other prognostic factors on the outcome of children with acute lymphoblastic leukemia (ALL) treated in recent trials is unknown. METHODS: Outcomes of 399 patients aged ≤18 years with newly diagnosed ALL who were enrolled in the Total Therapy XV study at St. Jude Children's Research Hospital were analyzed according to ALC at the end of remission induction therapy. RESULTS: An ALC ≥500 cells/μL was significantly more prevalent among patients with B-lineage ALL, in those with favorable presenting features, and in those who achieved negative minimal residual disease (MRD) status on day 43 of treatment. Both overall survival (OS) and event-free survival (EFS) were superior among patients with higher ALC, but only the association with OS was statistically significant in a univariate analysis. In multivariable analyses, ALC was not a significant predictor of outcome after controlling for age, leukocyte count, lineage, risk group, and MRD status at the end of induction (P > .1 for all comparisons). However, among MRD-negative patients, those with low ALC had a 5-year OS rate of 84.2% ± 8.9% versus 97.3% ± 1.0% for patients with higher ALC (P = .036). CONCLUSIONS: ALC at the end of induction is related to favorable presenting features and good initial treatment response but does not independently predict outcome in the context of contemporary, MRD-guided therapy.
Authors: E Coustan-Smith; J Sancho; M L Hancock; J M Boyett; F G Behm; S C Raimondi; J T Sandlund; G K Rivera; J E Rubnitz; R C Ribeiro; C H Pui; D Campana Journal: Blood Date: 2000-10-15 Impact factor: 22.113
Authors: Karen R Rabin; M Monica Gramatges; Michael J Borowitz; Shana L Palla; Xiaodong Shi; Judith F Margolin; Patrick A Zweidler-McKay Journal: Pediatr Blood Cancer Date: 2011-11-18 Impact factor: 3.167
Authors: D Behl; L F Porrata; S N Markovic; L Letendre; R K Pruthi; C C Hook; A Tefferi; M A Elliot; S H Kaufmann; R A Mesa; M R Litzow Journal: Leukemia Date: 2006-01 Impact factor: 11.528
Authors: Katharine C Hsu; Carolyn A Keever-Taylor; Andrew Wilton; Clara Pinto; Glenn Heller; Knarik Arkun; Richard J O'Reilly; Mary M Horowitz; Bo Dupont Journal: Blood Date: 2005-02-24 Impact factor: 22.113
Authors: E Coustan-Smith; F G Behm; J Sanchez; J M Boyett; M L Hancock; S C Raimondi; J E Rubnitz; G K Rivera; J T Sandlund; C H Pui; D Campana Journal: Lancet Date: 1998-02-21 Impact factor: 79.321
Authors: Wing Leung; Rekha Iyengar; Victoria Turner; Peter Lang; Peter Bader; Paul Conn; Dietrich Niethammer; Rupert Handgretinger Journal: J Immunol Date: 2004-01-01 Impact factor: 5.422
Authors: S Kumar; M G Chen; D A Gastineau; M A Gertz; D J Inwards; M Q Lacy; A Tefferi; M R Litzow Journal: Leukemia Date: 2003-09 Impact factor: 11.528
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Sumin Jo; Abbas Fotovati; Jesus Duque-Afonso; Michael L Cleary; Peter van den Elzen; Alix E Seif; Gregor S D Reid Journal: Cancers (Basel) Date: 2020-01-10 Impact factor: 6.639
Authors: Peter M Anderson; Stefanie M Thomas; Shauna Sartoski; Jacob G Scott; Kaitlin Sobilo; Sara Bewley; Laura K Salvador; Maritza Salazar-Abshire Journal: Nutrients Date: 2021-12-08 Impact factor: 5.717